Worldwide, clinical practice guidelines recommend treatment of most DKD patients with SGLT2 inhibitors regardless of the degree of glycemic control, based on the results of major randomized-control trials (RCTs) and their systematic review and meta-analysis [107,108]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.